PNNL

Abstract

The number of known circulating proteins that have potential for detecting cancer is rapidly growing. It seems clear, though, that variability in biomarker levels in both healthy and diseased populations will prevent most of these proteins from being useful. It also appears that a unique profile of biomarkers will be needed to accurately detect each type of cancer and that it will be necessary to evaluate blood samples from thousands of people to validate that profile. We are developing an antibody microarray platform that can be used to efficiently accomplish this task.